Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about RAF: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| Name | RAF |
| Key Genes/Proteins | AKT, ALZHEIMER, AND, APOPTOSIS, App, AUTOPHAGY |
| Related Diseases | Aging, Als, ALS, Alzheimer, ALZHEIMER'S |
| Related Pathways | Akt, Apoptosis, Autophagy |
Knowledge base pages for this entity
graph TD
RAF["RAF"]
style RAF fill:#1a237e,stroke:#4fc3f7,stroke-width:3px
RAF -->|"activates"| MEK([MEK])
RAF -->|"target for"| Ms["Ms"]
RAF -.->|"inhibits"| Cancer["Cancer"]
RAF -->|"target for"| Aging["Aging"]
RAF -->|"target for"| Lymphoma["Lymphoma"]
RAF -->|"target for"| Tumor["Tumor"]
RAF -->|"target for"| Als["Als"]
RAF -->|"activates"| RAS([RAS])
Vemurafenib{"Vemurafenib"} -.->|"inhibits"| RAF
NST_628{"NST-628"} -->|"binds to"| RAF
RAS -->|"activates"| RAF
AKT([AKT]) -->|"activates"| RAF
CANCER["CANCER"] -->|"activates"| RAF
ERK([ERK]) -->|"activates"| RAF
MTOR([MTOR]) -->|"activates"| RAF
PI3K([PI3K]) -->|"activates"| RAF| Target | Relation | Type | Str |
|---|---|---|---|
| Mapk Pathway | activates | pathway | 0.95 |
| MEK | activates | protein | 0.95 |
| MEK | phosphorylates | protein | 0.90 |
| cancer | associated_with | disease | 0.85 |
| oxidative stress response | participates_in | pathway | 0.70 |
| Cancer | inhibits | disease | 0.65 |
| Lymphoma | inhibits | disease | 0.65 |
| Stroke | activates | disease | 0.65 |
| Tumor | activates | disease | 0.65 |
| Tumor | inhibits | disease | 0.65 |
| ALS | regulates | disease | 0.65 |
| Parkinson | activates | disease | 0.65 |
| Als | therapeutic_target | disease | 0.65 |
| Ms | therapeutic_target | disease | 0.65 |
| ALS | interacts_with | disease | 0.65 |
| Cancer | activates | disease | 0.65 |
| Cancer | therapeutic_target | disease | 0.65 |
| Senescence | activates | disease | 0.65 |
| Aging | activates | disease | 0.65 |
| Inflammation | regulates | disease | 0.65 |
| Cancer | interacts_with | disease | 0.65 |
| Carcinoma | activates | disease | 0.65 |
| Aging | therapeutic_target | disease | 0.65 |
| Lymphoma | therapeutic_target | disease | 0.65 |
| Alzheimer | activates | disease | 0.65 |
| Neurodegeneration | regulates | disease | 0.65 |
| Aging | inhibits | disease | 0.65 |
| Tumor | therapeutic_target | disease | 0.65 |
| Fibrosis | inhibits | disease | 0.60 |
| Neuroinflammation | therapeutic_target | disease | 0.60 |
| Ferroptosis | inhibits | disease | 0.60 |
| Multiple Sclerosis | therapeutic_target | disease | 0.60 |
| Cancer | regulates | disease | 0.60 |
| Frontotemporal Dementia | causes | disease | 0.60 |
| Senescence | therapeutic_target | disease | 0.60 |
| Neurodegeneration | activates | disease | 0.60 |
| Amyotrophic Lateral Sclerosis | regulates | disease | 0.60 |
| Amyotrophic Lateral Sclerosis | causes | disease | 0.60 |
| Huntington | expressed_in | disease | 0.60 |
| Parkinson | expressed_in | disease | 0.60 |
| Alzheimer | expressed_in | disease | 0.60 |
| Dementia | causes | disease | 0.60 |
| Addiction | therapeutic_target | disease | 0.60 |
| Aging | expressed_in | disease | 0.60 |
| Frontotemporal Dementia | associated_with | disease | 0.60 |
| Amyotrophic Lateral Sclerosis | expressed_in | disease | 0.60 |
| Multiple Sclerosis | transports | disease | 0.60 |
| Depression | activates | disease | 0.60 |
| Diabetes | associated_with | disease | 0.60 |
| Dementia | associated_with | disease | 0.60 |
| Source | Relation | Type | Str |
|---|---|---|---|
| Vemurafenib | inhibits | drug | 0.90 |
| Dabrafenib | inhibits | drug | 0.90 |
| HSP90-CDC37 | interacts_with | protein | 0.90 |
| NST-628 | binds_to | drug | 0.88 |
| SHOC2 phosphatase complex | activates | protein | 0.85 |
| NATURAL PRODUCTS | regulates | compound | 0.80 |
| RAS | activates | protein | 0.80 |
| RAS | regulates | protein | 0.70 |
| PI3K | activates | gene | 0.65 |
| CANCER | inhibits | disease | 0.65 |
| ERK | activates | gene | 0.65 |
| CANCER | activates | disease | 0.65 |
| AKT | activates | gene | 0.65 |
| MTOR | activates | gene | 0.65 |
| H3F3A | associated_with | gene | 0.60 |
| TARDBP | regulates | gene | 0.60 |
| LAMP1 | regulates | gene | 0.60 |
| RNA | regulates | gene | 0.60 |
| OVERVIEW | biomarker_for | gene | 0.60 |
| BRAF | associated_with | gene | 0.60 |
| CIC | associated_with | gene | 0.60 |
| EIF4EBP1 | regulates | gene | 0.60 |
| MAP1LC3B | regulates | gene | 0.60 |
| PPARG | regulates | gene | 0.60 |
| CPT1A | regulates | gene | 0.60 |
| RPS6KB1 | regulates | gene | 0.60 |
| OVERVIEW | inhibits | gene | 0.60 |
| PPARA | regulates | gene | 0.60 |
| ATG | regulates | gene | 0.60 |
| ARF6 | interacts_with | gene | 0.60 |
| FTLD | expressed_in | gene | 0.60 |
| LRP2 | regulates | gene | 0.60 |
| ALS | expressed_in | gene | 0.60 |
| APOE4 | expressed_in | gene | 0.60 |
| DNA | regulates | gene | 0.60 |
| CTSD | regulates | gene | 0.60 |
| ATP | regulates | gene | 0.60 |
| NADH | regulates | gene | 0.60 |
| MTOR | regulates | gene | 0.60 |
| ALZHEIMER | expressed_in | gene | 0.60 |
| MTORC1 | regulates | gene | 0.60 |
| PIK3C3 | regulates | gene | 0.60 |
| CAT | regulates | gene | 0.60 |
| TDP-43 | regulates | gene | 0.60 |
| MITOCHONDRIA | activates | gene | 0.60 |
| RAB7A | regulates | gene | 0.60 |
| SREBF1 | regulates | gene | 0.60 |
| PPARGC1A | regulates | gene | 0.60 |
| RUBCN | regulates | gene | 0.60 |
| ACTB | regulates | gene | 0.60 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| IRI-AKI mouse model with mtROS inhibition | validation | ischemic acute kidney injury | 0.900 | 0.00 | IRI-AKI mice | proposed | N/A |
| mtROS effects on TFAM and mtDNA in HK2 cells | exploratory | acute kidney injury | 0.900 | 0.00 | HK2 cells | proposed | N/A |
| TFAM knockdown functional analysis | exploratory | acute kidney injury | 0.850 | 0.00 | HK2 cells | proposed | N/A |
| TFAM and mtDNA analysis in AKI patients | clinical | acute kidney injury | 0.800 | 0.00 | human patients | proposed | N/A |
| s:** - Test MCU overexpression specifically in layer II neurons in hea | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $200,000 |
| Proposed experiment from debate on Mitochondrial transfer between astr | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| Selective Vulnerability of Dopaminergic Neurons — Mechanism and Protec | validation | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $160,000 |
| Exercise-BDNF-Mitophagy Biomarker Study in PD | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Ferroptosis Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| GLP-1 Agonist Neuroprotection Mechanism in PD | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Chaperone-Mediated Autophagy Dysfunction in PD - Experiment Design | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Presymptomatic GRN Carrier Intervention Timing — Biomarker-Guided Ther | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Proteasome-Ubiquitin System Dysfunction Validation in Parkinson's Dise | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism and Therapeu | validation | Neurodegeneration | 0.400 | 0.50 | human | proposed | $2,730,000 |
| ER-Golgi Secretory Pathway Dysfunction in PD - Experiment Design | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Validation: Membrane-Nucleation in iPSC Neurons | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
| Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Designed endocytosis-inducing proteins degrade targets and amplify signals. [PMID:39322662] | Huang B, Abedi M, Ahn G, Coventry B, Sap | Nature | 2025 | 1 |
| Melatonin attenuates sepsis-induced acute kidney injury by promoting mitophagy t [PMID:37651673] | Deng Z, He M, Hu H, Zhang W, Zhang Y, Ge | Autophagy | 2024 | 1 |
| TFAM is an autophagy receptor that limits inflammation by binding to cytoplasmic [PMID:38783142] | Liu H, Zhen C, Xie J, Luo Z, Zeng L, Zha | Nat Cell Biol | 2024 | 1 |
| Collapse of late endosomal pH elicits a rapid Rab7 response via the V-ATPase and [PMID:38578235] | Mulligan RJ, Magaj MM, Digilio L, Redema | J Cell Sci | 2024 | 1 |
| IGF2 in memory, neurodevelopmental disorders, and neurodegenerative diseases. [PMID:37031050] | Alberini CM | Trends Neurosci | 2023 | 1 |
| Mitochondrial-derived damage-associated molecular patterns amplify neuroinflamma [PMID:35233090] | Lin MM, Liu N, Qin ZH, Wang Y | Acta Pharmacol Sin | 2022 | 1 |
| Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic [PMID:33408785] | Zhao M, Wang Y, Li L, Liu S, Wang C, Yua | Theranostics | 2021 | 1 |
| Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimer's Disease. [PMID:33803217] | Chang CH, Lin CH, Lane HY | Int J Mol Sci | 2021 | 1 |
| Mitochondrial DNA copy number in human disease: the more the better? [PMID:33314045] | Filograna R, Mennuni M, Alsina D, Larsso | FEBS Lett | 2021 | 1 |
| Mitochondrial DNA stress triggers autophagy-dependent ferroptotic death. [PMID:32186434] | Li C, Zhang Y, Liu J, Kang R, Klionsky D | Autophagy | 2021 | 1 |
| Interactions of IGF-II with the IGF2R/cation-independent mannose-6-phosphate rec [PMID:19251056] | Brown J, Jones EY, Forbes BE | Vitam Horm | 2009 | 1 |
| Butyrate extends health and lifespan in mice with mitochondrial deficiency. [PMID:41826362] | ["Gaband\u00e9-Rodr\u00edguez E", "G\u00 | Nature communications | 2026 | 0 |
| Vav-iCre-Mediated Deletion of TFAM Is Not Recoverable and Is Consistent with Emb [PMID:41898789] | ["Ghosh R", "Shakur E", "Yousefzadeh M"] | Genes | 2026 | 0 |
| ORMDL Proteins Turnover via Proteasome and Autophagy Is Cell-Type Dependent and [PMID:41806112] | Mrkacek M, Tumova M, Puskasu A, Utekal P | FASEB journal : official publi | 2026 | 0 |
| NRIP1 co-activates nuclear translocated FOXO3 to upregulate TFAM expression and [PMID:41888517] | ["Zha Y", "Huang H", "Liu Y", "Wan M", " | Cell death discovery | 2026 | 0 |
| miR-137-5p-Loaded Milk-Derived Small Extracellular Vesicles Modulate Oxidative S [PMID:41754992] | ["G\u00f6n\u00fcll\u00fc S", "Ayd\u0131n | Pharmaceutics | 2026 | 0 |
| Ginseng stem and leaf saponins attenuates pulmonary fibrosis by regulating TFAM- [PMID:41911987] | Chen Y, Hu L, Fu Q, Chen H, Jiang Z, Li | Journal of ethnopharmacology | 2026 | 0 |
| Amyloid-β fibrils accumulated in preeclamptic placentas suppress cytotrophoblast [PMID:41558820] | Nishioka K, Ikezaki M, Iwahashi N, Araka | Life Sci Alliance | 2026 | 0 |
| An anti-inflammatory neuroenhancer mitigates amyloid-β pathology to improve Alzh [PMID:41696149] | Fang W, Zhao J, Li L, Wang Y, Xu ZP et a | Mater Today Bio | 2026 | 0 |
| Intranasal administration of neural stem cell-derived extracellular vesicles pre [PMID:41923110] | Natale Francesca; Dellaria Alice; Nifo S | Alzheimer's research & the | 2026 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning RAF in their description or question text
Score: 0.694 · molecular biology · 2026-04-24
A plausible upstream submechanism is that lipid-poor APOE4 disrupts ABCA1 trafficking, likely via ARF6-associated endoso
Score: 0.693 · neurodegeneration · 2026-04-02
## Mechanistic Overview Palmitoylation-Targeted BACE1 Trafficking Disruptors starts from the claim that modulating BACE1
Score: 0.693 · neurodegeneration · 2026-04-26
Neurons express a distinct V-ATPase subunit isoform profile (ATP6V0C splice variants and ATP6V1G2 enrichment) resulting
Score: 0.692 · neurodegeneration · 2026-04-02
## Mechanistic Overview Sphingomyelin Synthase Activators for Raft Remodeling starts from the claim that modulating SGMS
Score: 0.649 · neurodegeneration · 2026-04-02
## Mechanistic Overview APOE-Mediated Synaptic Lipid Raft Stabilization starts from the claim that modulating SPTLC1 wit
Score: 0.610 · neuroscience · 2026-04-22
**Molecular Mechanism and Rationale** The apolipoprotein E4 (APOE4) isoform, present in approximately 25% of the popula
Score: 0.600 · neurodegeneration · 2026-04-22
## Mechanistic Overview H4: Hyperconnected Hub Status Creates Proteostatic Traffic Jams starts from the claim that modul
Score: 0.549 · neurodegeneration · 2026-04-02
Small molecule activators of Miro1 GTPase activity increase mitochondrial motility and facilitate intercellular transfer
Score: 0.520 · neuroscience · 2026-04-26
Local protein synthesis at synaptic compartments requires intact mRNA granule transport via ZBP1 and TDP-43 in granules.
Score: 0.517 · proteomics · 2026-04-25
VPS35 Retromer Restoration to Rescue Endosomal Protein Trafficking
Score: 0.460 · neurodegeneration · 2026-04-25
Aβ initially perturbs tau localization, but persistence depends on BIN1-regulated membrane and endocytic trafficking tha
Score: 0.000 · Parkinson's disease · 2026-04-26
We propose that GBA deficiency-driven accumulation of glucosylceramide (GlcCer) in lysosomal membranes creates ordered l
Score: 0.000 · proteomics · 2026-04-26
This hypothesis proposes that TFEB activation can restore synaptic function in aging by simultaneously upregulating both